EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 338 filers reported holding EXELIXIS INC in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,939,316 | -8.3% | 264,322 | -3.2% | 0.00% | 0.0% |
Q1 2024 | $6,477,080 | +7.0% | 272,949 | +8.1% | 0.00% | 0.0% |
Q4 2023 | $6,054,788 | +1.7% | 252,388 | -7.4% | 0.00% | -25.0% |
Q3 2023 | $5,952,879 | -25.3% | 272,443 | -34.7% | 0.00% | 0.0% |
Q2 2023 | $7,973,896 | +36.2% | 417,263 | +38.3% | 0.00% | +33.3% |
Q1 2023 | $5,856,385 | -85.7% | 301,720 | -88.2% | 0.00% | -87.5% |
Q4 2022 | $40,902,963 | +6.1% | 2,550,060 | +3.7% | 0.02% | +4.3% |
Q3 2022 | $38,557,000 | -47.4% | 2,458,974 | -30.1% | 0.02% | -43.9% |
Q2 2022 | $73,260,000 | +395.5% | 3,518,722 | +439.6% | 0.04% | +485.7% |
Q1 2022 | $14,784,000 | +7.3% | 652,100 | -13.5% | 0.01% | +16.7% |
Q4 2021 | $13,774,000 | -54.8% | 753,562 | -47.7% | 0.01% | -57.1% |
Q3 2021 | $30,446,000 | +20.7% | 1,440,213 | +4.0% | 0.01% | +16.7% |
Q2 2021 | $25,232,000 | -16.1% | 1,384,852 | +4.0% | 0.01% | -25.0% |
Q1 2021 | $30,078,000 | +762.8% | 1,331,486 | +666.8% | 0.02% | +700.0% |
Q4 2020 | $3,486,000 | -25.8% | 173,642 | -9.6% | 0.00% | -33.3% |
Q3 2020 | $4,698,000 | +25.5% | 192,151 | +21.8% | 0.00% | 0.0% |
Q2 2020 | $3,744,000 | -20.3% | 157,718 | -42.2% | 0.00% | -25.0% |
Q1 2020 | $4,696,000 | +164.7% | 272,788 | +170.4% | 0.00% | +300.0% |
Q4 2019 | $1,774,000 | -8.5% | 100,882 | -8.1% | 0.00% | 0.0% |
Q3 2019 | $1,939,000 | -89.5% | 109,829 | -87.3% | 0.00% | -90.9% |
Q2 2019 | $18,427,000 | -54.6% | 862,396 | -49.4% | 0.01% | -54.2% |
Q1 2019 | $40,589,000 | +44.8% | 1,705,602 | +19.7% | 0.02% | +20.0% |
Q4 2018 | $28,035,000 | -58.2% | 1,425,417 | -62.3% | 0.02% | 0.0% |
Q3 2018 | $67,080,000 | -58.4% | 3,785,717 | -49.4% | 0.02% | -56.5% |
Q2 2018 | $161,158,000 | +369.6% | 7,488,889 | +383.3% | 0.05% | +187.5% |
Q1 2018 | $34,318,000 | +48.8% | 1,549,444 | +104.1% | 0.02% | +6.7% |
Q4 2017 | $23,069,000 | +34.5% | 758,981 | +7.2% | 0.02% | +25.0% |
Q3 2017 | $17,155,000 | -44.4% | 708,104 | -43.4% | 0.01% | -45.5% |
Q2 2017 | $30,832,000 | +52.3% | 1,251,892 | +34.0% | 0.02% | +46.7% |
Q1 2017 | $20,243,000 | +65.1% | 934,243 | +13.6% | 0.02% | +50.0% |
Q4 2016 | $12,258,000 | -31.2% | 822,355 | -41.0% | 0.01% | -23.1% |
Q3 2016 | $17,819,000 | +339.4% | 1,393,413 | +168.2% | 0.01% | +333.3% |
Q2 2016 | $4,055,000 | -18.0% | 519,522 | -58.0% | 0.00% | -25.0% |
Q1 2016 | $4,944,000 | -54.3% | 1,236,498 | -35.5% | 0.00% | -42.9% |
Q4 2015 | $10,808,000 | +1962.6% | 1,916,486 | +1941.9% | 0.01% | – |
Q3 2015 | $524,000 | +168.7% | 93,858 | +79.6% | 0.00% | – |
Q2 2015 | $195,000 | -59.6% | 52,266 | -72.3% | 0.00% | – |
Q1 2015 | $483,000 | +205.7% | 188,672 | +68.6% | 0.00% | – |
Q4 2014 | $158,000 | -8.7% | 111,907 | -2.2% | 0.00% | – |
Q3 2014 | $173,000 | -98.2% | 114,370 | -95.9% | 0.00% | -100.0% |
Q2 2014 | $9,460,000 | +18.9% | 2,791,176 | +24.0% | 0.01% | 0.0% |
Q1 2014 | $7,956,000 | -44.7% | 2,250,343 | -4.2% | 0.01% | -40.0% |
Q4 2013 | $14,393,000 | -6.2% | 2,350,085 | -11.0% | 0.01% | -9.1% |
Q3 2013 | $15,348,000 | – | 2,639,525 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |